Oruka Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +19.3% | -26.4% | -90.6% | +107.7% | -26.0% | +78.1% | -92.9% | -39.5% | -53.8% | +58.3% | +26.3% | +12.5% | -18.5% | +304.5% | +4.5% | -2.2% | +25.3% | -76.3% | +207.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +440.9% | -190.3% | – | -9,478.6% | – | – | – | – | -133.0% | – | +284.6% | -78.8% | -815.3% | – | +325.6% | -101.5% | – | – | -122.0% | |
| – | -5.0% | -84.4% | +252.8% | -86.2% | -97.8% | +375.1% | -100.0% | – | -40.6% | -42.1% | +9.1% | -75.0% | +33.3% | +0.0% | +375.0% | +126.3% | -95.3% | +9,350.0% | +10.6% | |
| – | +5,182.0% | – | -112.0% | – | -99.4% | +657.0% | – | – | -40.6% | -42.1% | +149,118.2% | – | -76.4% | -100.1% | +375.0% | +126.3% | -95.3% | +16,506,250.0% | -70.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +49.9% | -102.8% | – | -130.3% | – | -47.1% | -72.7% | +1,715.7% | -58.1% | +323.7% | – | – | -46.9% | +111.3% | +638.6% | -52.3% | – | – | -62.1% | |
| – | -40.2% | -225.3% | – | – | -3,308.7% | – | – | – | -110.1% | – | -233.9% | – | -261.0% | – | +2,219.5% | -89.5% | -354.5% | – | -160.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.